Abstract

For FY13, the Integrated Research Facility in the Division of Clinical Research has significantly increased the level of research facilitation that it provides. Primarily, this support has been directed to facilitating the biodefense and emerging infectious disease research of the Emerging Viral Pathogens section in the Division of Intramural Research, reported separately. In addition, core capabilities of the IRF have been established to include clinical pathology, anatomic pathology, electron microscopy, confocal microscopy, immunology, and cell culture. Rodents were introduced into the facility in Nov 2012 followed by primates in December of the same year. Medical imaging using all four modalities on uninfected animals was initiated in January 2013 followed by infections non-Select Agents in March and aerosol infectivity studies in April, plus influenza and MERS in July.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Clinical Support Services Intramural Research (ZID)
Project #
1ZIDAI009006-05
Application #
8745795
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2013
Total Cost
$19,981,023
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Shantha, Jessica G; Mattia, John G; Goba, Augustine et al. (2018) Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone. EBioMedicine 30:217-224
Jensen, Kenneth S; Adams, Ricky; Bennett, Richard S et al. (2018) Development of a novel real-time polymerase chain reaction assay for the quantitative detection of Nipah virus replicative viral RNA. PLoS One 13:e0199534
Tamhankar, Manasi; Gerhardt, Dawn M; Bennett, Richard S et al. (2018) Heparan sulfate is an important mediator of Ebola virus infection in polarized epithelial cells. Virol J 15:135
DeWald, Lisa Evans; Dyall, Julie; Sword, Jennifer M et al. (2018) The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease. J Infect Dis :
Ward-Kavanagh, Lindsay K; Kokolus, Kathleen M; Cooper, Timothy K et al. (2018) Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors. Cancer Immunol Immunother 67:639-652
Cong, Yu; Hart, Brit J; Gross, Robin et al. (2018) MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS One 13:e0194868
Pleet, Michelle L; Erickson, James; DeMarino, Catherine et al. (2018) Ebola Virus VP40 Modulates Cell Cycle and Biogenesis of Extracellular Vesicles. J Infect Dis :
Postnikova, Elena; Cong, Yu; DeWald, Lisa Evans et al. (2018) Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. PLoS One 13:e0194880
Dyall, Julie; Johnson, Joshua C; Hart, Brit J et al. (2018) In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus. J Infect Dis :
Dyall, Julie; Nelson, Elizabeth A; DeWald, Lisa Evans et al. (2018) Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. J Infect Dis :

Showing the most recent 10 out of 85 publications